Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Post-hoc analysis (n=3,730) found notable differences in cardiovascular death/hospitalisation for heart failure according to race (from 34.4 events per 100 patient years for Black people to 18.7 for White). Groups with the highest rates had the greatest benefit from empagliflozin
Source:
European Heart Journal